These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1348595)

  • 1. Preliminary human trial of inactivated golden hamster kidney cell (GHKC) vaccine against haemorrhagic fever with renal syndrome (HFRS).
    Song G; Huang YC; Hang CS; Hao FY; Li DX; Zheng XL; Liu WM; Li SL; Huo ZW; Huei LJ
    Vaccine; 1992; 10(4):214-6. PubMed ID: 1348595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody responses in humans to an inactivated hantavirus vaccine (Hantavax).
    Cho HW; Howard CR
    Vaccine; 1999 Jun; 17(20-21):2569-75. PubMed ID: 10418904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of inactivated vaccine containing cyto-hemagglutinin against epidemic hemorrhagic fever in rabbits.
    Zhu ZY; Tang HY; Li YJ; Weng JQ; Fu GM
    Chin Med J (Engl); 1989 Aug; 102(8):602-5. PubMed ID: 2576866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective Effectiveness of Inactivated Hantavirus Vaccine Against Hemorrhagic Fever With Renal Syndrome.
    Jung J; Ko SJ; Oh HS; Moon SM; Song JW; Huh K
    J Infect Dis; 2018 Apr; 217(9):1417-1420. PubMed ID: 29373686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of an inactivated vaccine against hantaviruses.
    Cho HW; Howard CR; Lee HW
    Intervirology; 2002; 45(4-6):328-33. PubMed ID: 12602351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responses to inactivated vaccine in people naturally infected with hantaviruses.
    Lu Q; Zhu Z; Weng J
    J Med Virol; 1996 Aug; 49(4):333-5. PubMed ID: 8877768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Preventive effects of three kinds of inactive vaccines against epidemic hemorrhagic fever (EHF) after 5 years of vaccination].
    Chen H; Tang L; Luo Z; Zhang J; Zhang Z; Hu M; Weng J; Liu W; Zhao T; Liu W
    Zhonghua Liu Xing Bing Xue Za Zhi; 2000 Oct; 21(5):347-8. PubMed ID: 11860813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative study on antibody levels of vaccination group and control group after 4 years of immunized with type B inactivated vaccine against hemorrhagic fever with renal syndrome].
    Ruan Y; Liu W; Xu X; Weng SQ; Shao SK; Zhou WQ; Teng Z; Gu HX; Zhu ZY; Xu ZY
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Sep; 15(3):274-6. PubMed ID: 11986705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of immune responses to vaccine against haemorrhagic fever with renal syndrome in healthy adults aged 16-60 years: results from an open-label2-year follow-up study.
    Zheng Y; Zhou BY; Wei J; Xu Y; Dong JH; Guan LY; Ma P; Yu PB; Wang JJ
    Infect Dis (Lond); 2018 Jan; 50(1):21-26. PubMed ID: 28703073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation on inactivated epidemic hemorrhagic fever tissue culture vaccine in humans.
    Zhu ZY; Tang HY; Li YJ; Weng JQ; Yu YX; Zeng RF
    Chin Med J (Engl); 1994 Mar; 107(3):167-70. PubMed ID: 7916278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine.
    Yoo YC; Yoshimatsu K; Koike Y; Hatsuse R; Yamanishi K; Tanishita O; Arikawa J; Azuma I
    Vaccine; 1998; 16(2-3):216-24. PubMed ID: 9607033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A study on immunogenicity and safety of bivalent inactivated vaccine against hemorrhagic fever with renal syndrome].
    Ruan Y; Xu X; Liu W; Deng X; Weng S; Zhou W; Wang Q; Chen L; Fang L; Xu Z; Yan Q; Liu W; Dong G; Gu H; Yu Y; Xu Z
    Zhonghua Yu Fang Yi Xue Za Zhi; 1999 Nov; 33(6):340-2. PubMed ID: 11864504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary trials of inactivated vaccine against haemorrhagic fever with renal syndrome.
    Song G; Hang CS; Huang YC; Hou FY
    Lancet; 1991 Mar; 337(8744):801. PubMed ID: 1672432
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term persistence of anti-hantavirus antibodies in sera of patients undergoing hemorrhagic fever with renal syndrome and subjects vaccinated against the disease.
    Zheng Y; Wei J; Zhou BY; Xu Y; Dong JH; Guan LY; Ma P; Yu PB; Wang JJ
    Infect Dis (Lond); 2016 Apr; 48(4):262-266. PubMed ID: 26654580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against seoul virus infection.
    Hooper JW; Kamrud KI; Elgh F; Custer D; Schmaljohn CS
    Virology; 1999 Mar; 255(2):269-78. PubMed ID: 10069952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS).
    Hooper JW; Josleyn M; Ballantyne J; Brocato R
    Vaccine; 2013 Sep; 31(40):4314-21. PubMed ID: 23892100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiological progresses of hemorrhagic fever with renal syndrome in China.
    Song G
    Chin Med J (Engl); 1999 May; 112(5):472-7. PubMed ID: 11593522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation.
    Hooper JW; Moon JE; Paolino KM; Newcomer R; McLain DE; Josleyn M; Hannaman D; Schmaljohn C
    Clin Microbiol Infect; 2014 May; 20 Suppl 5():110-7. PubMed ID: 24447183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Safety and immunogenicity of inactivated bivalent EHF vaccine in humans].
    Liu W; Xu X; Ruan Y; Weng S; Liu W; Zhou W; Dong G; Gu H; Zhu Z; Xu Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 2000 Dec; 21(6):445-7. PubMed ID: 11860832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term immunogenicity and safety of inactivated Hantaan virus vaccine (Hantavax™) in healthy adults.
    Song JY; Woo HJ; Cheong HJ; Noh JY; Baek LJ; Kim WJ
    Vaccine; 2016 Mar; 34(10):1289-95. PubMed ID: 26826547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.